srch

BLUEPRINT MEDICINES (UK) LTD. is located in LONDON, United Kingdom and is part of the Pharmaceutical and Medicine Manufacturing Industry. BLUEPRINT MEDICINES (UK) LTD. has 4 employees at this location and generates $291,897 in sales (USD). (Employees figure is estimated). There are 8 companies in the BLUEPRINT MEDICINES (UK) LTD. corporate family.

BLUEPRINT MEDICINES (UK) LTD. - Free company information from Companies House including registered office address, filing history, accounts, annual return, ...

Blueprint Medicines is uniquely positioned to develop medicines that may benefit patients with the highest unmet need. Beyond this, our work may potentially drive healthcare systems worldwide to rethink how to diagnose and treat cancers and rare diseases.

Free company summary for BLUEPRINT MEDICINES (UK) LTD. including Companies house registration, overview of business activities, contact details, ...

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

09.12.2021 · Blueprint Medicines Corporation (NASDAQ:BPMC) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for BPMC is 79.8 ...

Blueprint Medicines (Uk) Ltd. United Kingdom. Blueprint Medicines Spain, S.L.. Spain.

31.12.2021 · Shares of Blueprint Medicines Corporation BPMC have rallied 24.8% in the past six months against the industry’s decrease of 18.7%. Image Source: Zacks Investment Research The company has made steady progress with its lead drug, Ayvakit (avapritinib), approved by the FDA for the treatment of adult ...

Dec 31, 2021 · Shares of Blueprint Medicines Corporation BPMC have rallied 24.8% in the past six months against the industry’s decrease of 18.7%. Image Source: Zacks Investment Research The company has made steady progress with its lead drug, Ayvakit (avapritinib), approved by the FDA for the treatment of adult ...

BLUEPRINT MEDICINES (UK) LTD. is located in LONDON, United Kingdom and is part of the Pharmaceutical and Medicine Manufacturing Industry. BLUEPRINT MEDICINES (UK) LTD. has 4 employees at this location and generates $291,897 in sales (USD). (Employees figure is estimated). There are 8 companies in the BLUEPRINT MEDICINES (UK) LTD. corporate family.

Blueprint Medicines makes kinase drugs to treat patients with genomically defined ... Italy, Spain, the United Kingdom and Japan, or the Major Markets; ...

03.12.2021 · Blueprint Medicines Corporation’s BPMC lead drug, Ayvakit (avapritinib), was approved by the FDA for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, in January 2020.The European Commission has granted …

Blueprint Medicines | 23408 followers on LinkedIn. Staying one step ahead of disease | Blueprint Medicines is a global precision therapy company that ...

Blueprint Medicines (UK) Ltd is an active company incorporated on 3 July 2019 with the registered office located in London, Greater London.

Find company research, competitor information, contact details & financial data for Blueprint Medicines Corporation of Cambridge, MA.

15.12.2020 · Blueprint Medicines is headquartered in the U.S. and as a result, personal information about you will be processed by Blueprint Medicines in the U.S. Blueprint Medicines may contract with service providers to process personal information on Blueprint Medicine’s behalf; these service providers may be located outside of the EEA, Switzerland and UK.

1 day ago · Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a ...

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.